Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.
暂无分享,去创建一个
David J. Daniels | P. Law | N. Lenard | P. Portoghese | D. J. Daniels | Christopher L. Etienne | S. Roerig | Philip S Portoghese | Ping-Yee Law | David J Daniels | Natalie R Lenard | Chris L Etienne | Sandra C Roerig | N. R. Lenard
[1] P. Portoghese,et al. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. , 1991, The Journal of pharmacology and experimental therapeutics.
[2] Jamie Fong,et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Schulz,et al. Opiate receptor binding studies in the mouse vas deferens exhibiting tolerance without dependence , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.
[4] H. Loh,et al. Simultaneous quantitative assessment of morphine tolerance and physical dependence. , 1969, The Journal of pharmacology and experimental therapeutics.
[5] D. Taylor,et al. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. , 2001, The Journal of pharmacology and experimental therapeutics.
[6] D. L. Larson,et al. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. , 1986, Journal of medicinal chemistry.
[7] A. Takemori,et al. Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. , 1979, The Journal of pharmacology and experimental therapeutics.
[8] D. L. Larson,et al. Hybrid bivalent ligands with opiate and enkephalin pharmacophores. , 1987, Journal of medicinal chemistry.
[9] W. Bowen,et al. Lack of involvement of delta-1 opioid receptors in the development of physical dependence on morphine in mice. , 1994, The Journal of pharmacology and experimental therapeutics.
[10] P. Munson,et al. Dimeric pentapeptide enkephalin: a novel probe of delta opiate receptors. , 1982, Life sciences.
[11] David J. Daniels,et al. Interaction of Bivalent Ligand KDN21 with Heterodimeric δ-κ Opioid Receptors in Human Embryonic Kidney 293 Cells , 2005, Molecular Pharmacology.
[12] R. Rothman,et al. Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. , 1982, Life sciences.
[13] T. Coderre,et al. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ] , 1995 .
[14] Lakshmi A. Devi,et al. A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia , 2004 .
[15] D. L. Larson,et al. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. , 1985, Journal of medicinal chemistry.
[16] T. Haley,et al. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. , 1957, British journal of pharmacology and chemotherapy.
[17] P. Portoghese,et al. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. , 2001, Journal of medicinal chemistry.
[18] A. Kolinski,et al. 2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvitamin D(3): synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. , 2002, Journal of medicinal chemistry.
[19] S K Saini,et al. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. , 1999, Journal of medicinal chemistry.
[20] Y. Imanishi,et al. Binding to opioid receptors of enkephalin derivatives taking alpha-helical conformation and its dimer. , 2009, International journal of peptide and protein research.
[21] Peter W. Schiller,et al. The Opioid μ Agonist/δ Antagonist DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats , 1999 .
[22] Joshua F. Nitsche,et al. Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice , 1999, Neuron.
[23] David J. Daniels,et al. A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .
[24] Fred E. D'Amour,et al. A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .
[25] A. García-España,et al. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[26] P. Portoghese,et al. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. , 1990, Journal of medicinal chemistry.
[27] D. Rodbard,et al. Dimeric tetrapeptide enkephalins display extraordinary selectivity for the δ opiate receptor , 1982, Nature.
[28] J. Levine,et al. Different Mechanisms Mediate Development and Expression of Tolerance and Dependence for Peripheral μ-Opioid Antinociception in Rat , 1997, The Journal of Neuroscience.
[29] B. O'dowd,et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.
[30] B. Kest,et al. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice , 1996, Brain Research Bulletin.
[31] D. L. Larson,et al. Opioid agonist and antagonist bivalent ligands as receptor probes. , 1982, Life sciences.
[32] L. Devi,et al. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.
[33] O. Andreassen,et al. Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.
[34] J. L. Wells,et al. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. , 2001, The Journal of pharmacology and experimental therapeutics.
[35] P. Portoghese,et al. Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites , 1982 .
[36] D. Rodbard,et al. Receptor binding and biological activity of bivalent enkephalins. , 1985, Biochemical pharmacology.
[37] P. Portoghese,et al. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. , 1993, The Journal of pharmacology and experimental therapeutics.
[38] P. Cuatrecasas,et al. Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking. , 1982, Biochemical and biophysical research communications.
[39] David J. Daniels,et al. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. , 2004, Journal of medicinal chemistry.